MedTrace Logo

Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

NCT07325955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 194

Last updated 2026-01-08

No results posted yet for this study

Summary

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Conditions

  • ST Elevation Myocardial Infarction (STEMI)

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-07-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07325955 on ClinicalTrials.gov